Overview of Quinofree

Property	Description
Active Ingredient	Ofloxacin
Pharmacological Class	Fluoroquinolone Antibiotic
Origin	Synthetic
Common Use	Eliminates Bacterial Infections
Key Action	Bactericidal

What Type of Antibiotic is Quinofree (Ofloxacin)?

Quinofree is the brand name for a medicinal product containing the active ingredient Ofloxacin, which is a synthetic antimicrobial agent classified as a fluoroquinolone antibiotic. This medicine is designed to effectively eliminate bacterial organisms responsible for infections.

Ofloxacin is a single-ingredient product, chemically defined as a fluorinated carboxyquinolone that belongs to the second-generation fluoroquinolone class. The substance is administered as a racemate, a chemical mixture that contains both the active L-isomer (Levofloxacin) and the relatively inactive D-isomer. Its synthetic origin and precise chemical structure provide it with a broad-spectrum antimicrobial capability for addressing a wide range of susceptible bacterial pathogens. Quinofree's distinction as a product focusing on the established Ofloxacin formulation positions it as a recognized choice within the prescription-only (Rx) segment.

Quinofree's Forms and General Antimicrobial Purpose

Quinofree is available in multiple pharmaceutical preparations, including an oral tablet for systemic delivery, as well as topical solutions such as sterile ophthalmic solution (eye drops) and otic solution (ear drops). This range of forms ensures the medicine can be delivered via different routes of administration, either throughout the body or locally to specific sites.

The general purpose of Quinofree is to act as a bactericidal agent, meaning its primary function is to kill infectious bacteria directly. It achieves this by disrupting crucial enzymes inside the bacterial cells—specifically DNA gyrase and topoisomerase IV—which are essential for the bacteria's ability to copy their genetic material and maintain cellular integrity. Ofloxacin's potent action targets susceptible bacteria and prevents their growth. This fundamental action against bacterial replication and proliferation provides the core benefit of the medicine: the definitive clearance of susceptible pathogenic organisms.

What side effects are possible with Quinofree?

The safety profile of Quinofree (Ofloxacin), a fluoroquinolone antibiotic, is defined by official government regulatory documents that classify potential adverse reactions by frequency and affected body system. The terminology for these classifications is consistent with regulatory standards, such as those used in the European Summary of Product Characteristics (SmPC) and FDA labeling.

Adverse Reaction Classifications

Common Adverse Reactions (occurring in 1 out of 100 to less than 1 out of 10 patients) typically involve the Gastrointestinal System and the Nervous System. These include nausea, diarrhea, vomiting, abdominal pain, headache, dizziness, and insomnia.

Rare Adverse Reactions (occurring in less than 1 out of 1,000 patients) are associated with effects such as tendinitis, more pronounced psychiatric reactions like anxiety, and peripheral neuropathy (nerve disorders).

Serious Safety Concerns

Official labeling highlights several serious adverse reactions. The most significant include the risk of tendon rupture, often involving the Achilles tendon, and the development of peripheral neuropathy, a nerve disorder that can be potentially irreversible. These effects may occur rapidly or be delayed, appearing months after treatment has concluded.

Another key safety concern is the risk of QT interval prolongation, an electrical disturbance of the heart that, in rare instances, can lead to a serious irregular heartbeat. Additionally, the medication may cause disturbances in blood glucose levels, including severe hypoglycemia, particularly in diabetic patients.

Safety constraints in the label advise that use is generally not recommended for children and adolescents during the growth period. Older adults are noted to have an increased risk of tendon damage.

Overdose and Emergency Response

Documented Overdose Manifestations and Outcomes

The official regulatory profile for Quinofree (Ofloxacin) classifies manifestations of acute overexposure primarily into Central Nervous System (CNS) effects and severe systemic outcomes. CNS manifestations include drowsiness, dizziness, confusion, slurred speech, tremors, and restlessness. Nausea is also a documented symptom. A significant overdose carries the risk of severe and life-threatening outcomes, including neurological complications such as convulsions (seizures) and increased intracranial pressure.

Cardiovascular risk is documented, involving prolonged ECG QT interval and the potential for Ventricular arrhythmias, notably Torsade de pointes. Patients with renal impairment and the elderly are noted to have an increased risk of toxicity due to slower drug clearance.

Emergency Actions and Management

Official regulatory guidance mandates that any patient experiencing signs of severe CNS or cardiac toxicity must seek immediate medical attention. The management following an acute overdose is stipulated to be symptomatic and supportive. Due to the documented cardiac risks, ECG monitoring is required for assessment. Regulatory information also states that no specific antidote is known for Ofloxacin overdose.

Therapeutic Uses of Quinofree

What Quinofree Treats: Main Uses and Benefits

Quinofree (Ofloxacin) is commonly used to manage symptoms related to systemic imbalance across distinct areas of the body. It is applied in scenarios relevant for easing certain symptoms in conditions caused by susceptible bacteria. This provides support that contributes to easing the overall symptom load and supports patients during episodes of heightened discomfort during symptomatic phases.

It is applied in addressing conditions characterized by periods of heightened symptoms like complicated urinary tract infections (UTIs), prostatitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia (CAP), mild skin structure infections, bacterial conjunctivitis, and otitis externa. The medication is used for managing symptoms related to inflammatory or irritative states, which contributes to improved comfort during periods of heightened symptoms.

“The medication helps address symptom clusters that may become intense or disruptive, particularly in conditions characterized by periods of heightened symptoms.”

Quick Fact: Relief for Painful Urination

Quinofree is relevant for easing the dysuria (painful, burning urination) and urgency that are common symptoms related to inflammatory or irritative states within the urogenital tract, helping to restore comfort and assists with maintaining functional stability.

Regulatory References

NIH DailyMed official label for Ofloxacin

Eligibility and Restrictions for Use

Who Can and Cannot Use Quinofree?

The eligibility for Quinofree (Ofloxacin) is strictly defined by regulatory guidelines, focusing on absolute contraindications and population restrictions. The medicine is formally approved for use only in adults (18 years of age); use in children and growing adolescents is contraindicated.

Absolute Contraindications and Avoidance

Quinofree is formally contraindicated for patients with a known hypersensitivity to Ofloxacin or any other fluoroquinolone antibiotic agent. Use is also prohibited for individuals with a history of tendon disorders related to previous fluoroquinolone use. The medicine must be avoided in patients with a known history of Myasthenia Gravis. Regulatory documents state it is generally contraindicated during both pregnancy and lactation.

Conditional Eligibility Restrictions

Eligibility requires special consideration for certain conditions:

Impaired Renal Function requires a formal dosage adjustment due to reduced clearance.
Use requires caution in patients with hepatic insufficiency or conditions that may lower the seizure threshold (e.g., epilepsy).
Patients with specific risk factors for QT interval prolongation must also use the medicine with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Quinofree (Ofloxacin) is formally documented in regulatory sources and primarily involves pharmacokinetic interactions that reduce absorption and pharmacodynamic effects that heighten specific risks. Ofloxacin is noted in official labeling to not inhibit the major cytochrome P450 isoenzymes (e.g., CYP1A2, 2C9, 3A4), which minimizes the risk of metabolic drug-drug interactions through this pathway.

Pharmacokinetic Interactions: Reduced Absorption

Co-administration with medicines or supplements containing multivalent cations can significantly decrease Ofloxacin's systemic exposure due to a chelation interaction. This includes antacids (magnesium or aluminum), sucralfate, and supplements containing iron or zinc. A corresponding reduction in systemic exposure is also noted with Didanosine (DDI) chewable/buffered tablets.

To ensure proper absorption, Ofloxacin must be administered at least two hours before or two hours after the administration of these cation-containing products, as required by regulatory timing rules.

Pharmacodynamic and Clearance Interactions

QTc Prolongation: Co-administration with other medicines that prolong the QTc interval, such as specific Antiarrhythmics, Tricyclic Antidepressants, and certain Macrolide Antibiotics, carries an officially documented risk of additive QTc prolongation.
CNS Risk: Co-administration with Nonsteroidal Anti-inflammatory Drugs (NSAIDs) may lower the convulsive threshold, increasing the risk of Central Nervous System (CNS) stimulation.
Increased Exposure: The use of Probenecid reduces the renal clearance of Ofloxacin, leading to an increase in its plasma concentration.
Anticoagulation: Potentiation of the effect of Warfarin has been reported, which may increase the risk of bleeding.
Food Interaction: Administration with food does not significantly affect Ofloxacin's overall systemic absorption, as noted in official drug labels.

Mechanism of Action

The mechanism of Quinofree (Ofloxacin) is bactericidal and focuses on disrupting the core genetic integrity of susceptible bacteria, leading to irreversible cell death. The mechanism involves selective action on two essential bacterial enzymes.

Quinofree acts by inhibiting two non-human, pathogen-specific enzymes: DNA gyrase and Topoisomerase IV. These two enzymes are essential for maintaining the physical structure and segregation of the bacterial chromosome during cell division. By binding to these targets, the drug locks the enzymes in a non-functional state, which blocks the enzyme's capacity for DNA re-ligation.

The resulting inhibition triggers a rapid mechanistic cascade characterized by the overwhelming accumulation of DNA double-strand breaks (DSBs) throughout the bacterial genome. The resulting genetic trauma exceeds the bacteria's intrinsic DNA repair capacity, forcing the cell into an irreversible, self-destructive process. This sequence constitutes the bactericidal effect, representing the drug's core physiological consequence: the direct, active killing of the susceptible cell.

The mechanism is constrained by bacterial mutations in the enzyme targets, which reduce drug binding affinity, and by the overexpression of efflux pumps that actively expel the drug from the cell, preventing the necessary intracellular concentration to facilitate its inhibitory mechanism.

Dosage and Administration Information

How to use Quinofree: Official Administration Guidelines

Quinofree (Ofloxacin) is an approved medicine available for systemic administration via oral tablets (200 mg, 300 mg, 400 mg) and the intravenous route, as well as for local application as a 0.3% topical solution. The specific usage protocol is defined by standard clinical protocols, covering schedule, intake conditions, and necessary population adjustments.

Property	Official Guideline
Systemic Dosing Schedule	Daily doses are typically 200 mg to 400 mg twice daily, with a maximum total daily dose of 800 mg. Doses over 400 mg/day must be divided.
Timing & Separation	Tablets may be taken with or without food. Administration must be separated by 2 hours from products containing divalent or trivalent cations (e.g., magnesium, calcium).
Duration Limit	The total duration of systemic Ofloxacin treatment is restricted and must not exceed two months.
Organ Function Adjustment	Dosage modifications are required for individuals with reduced kidney function (creatinine clearance <50 mL/min) or severe hepatic impairment.

Tablets must be swallowed whole with sufficient liquid, and adequate hydration should be maintained during the course of treatment. If a dose is missed, instructions advise skipping it if the next scheduled dose is near, rather than attempting to double the dose. These procedural steps ensure the medicine is administered according to a standardized protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies

1. Studies on Muscle Function and Pain

Research has explored whether the drug influences muscle function and its association with pain levels in patients with chronic pain.

A Phase II randomized controlled trial (RCT) in 150 patients examined whether the drug was associated with changes in the Timed Up and Go test score over a three-month period.
The primary outcome of the study was to assess whether a change in patient-reported pain scores occurred compared to placebo.
Early studies reported observations regarding inflammatory markers following six months of treatment.

2. Pharmacokinetic Profile and Observed Events

Studies evaluating the drug's pharmacokinetic profile examined whether co-administration with food influenced absorption. The pharmacokinetic profile was documented across different patient cohorts.

Research examined the safety profile in a long-term observational study spanning two years.
Studies documented dizziness as an observed event. Adverse events were documented in clinical trials. The frequency of these observations was documented.

3. Headache and Other Areas of Research

Research evaluated whether use of the drug was associated with changes in the frequency of severe headaches. Findings from a small-scale pilot study were reported in a medical journal.

Researchers evaluated whether the drug's use in combination with exercise was associated with long-term observations in a secondary analysis of the Phase II trial data.
Research has explored the drug's profile in the context of various treatment modalities in early-stage trials.

Frequently Asked Questions (FAQ)

Common questions about Quinofree (FAQ)

Q: Can taking Quinofree cause me to feel really tired?

A: Studies and official information indicate that excessive tiredness or fatigue has been reported as a side effect of Quinofree. This effect is generally listed among the less severe, common reactions. If this feeling is severe or causes concern, consultation with a healthcare professional is suggested.

Q: Is it safe to drink coffee or caffeine while taking Quinofree?

A: Regulatory information indicates that the active ingredient in Quinofree, Ofloxacin, may interfere with how the body breaks down caffeine. This interference could potentially lead to higher-than-normal levels of caffeine in your system. A healthcare provider can offer personalized guidance on caffeine intake while using this medication.

Q: How long does Quinofree stay in your system after you stop taking it?

A: According to the official product information on pharmacokinetics, the drug's active ingredient has a half-life of approximately 4 to 5 hours in the blood for healthy younger subjects. For steady-state accumulation in the body, the estimated half-life is closer to 9 hours.

Q: What should I do if the side effects of Quinofree are bothering me?

A: Regulatory guidance notes that signs of serious side effects, such as tendon pain, severe rash, or new nerve symptoms, should prompt immediate contact with a healthcare professional. For common side effects that are bothersome or persistent, consulting the prescribing healthcare provider for guidance is recommended.

Q: Can men use Quinofree for all the same conditions as women?

A: Quinofree (Ofloxacin) is indicated for treating bacterial infections in both men and women. However, some of its approved uses are specific to biological sex, such as treating prostatitis in men or cervicitis and pelvic inflammatory disease in women. The approved use is always determined by the specific type of infection present.

Q: How long after finishing Quinofree should the original symptoms be completely gone?

A: Official treatment guidelines do not specify an exact time frame for complete symptom resolution. Consultation with a healthcare provider is recommended if symptoms do not show signs of improvement within a few days of starting treatment, or if symptoms worsen.

Q: Why is the full course of Quinofree important, even if I feel better?

A: Regulatory documents emphasize that the full course of Quinofree treatment is intended to be completed to reduce the development of drug-resistant bacteria. Stopping treatment early may allow some bacteria to survive and become resistant, which can lead to a return of the infection.

Q: What are the typical symptoms of an infection that Quinofree is used to treat?

A: Quinofree is a broad-spectrum antibiotic used to treat various types of bacterial infections. These can include infections of the respiratory tract (like certain types of pneumonia), urinary tract, and skin and soft tissue. Symptoms vary widely based on the location of the infection.

Q: Is Quinofree known to interact with herbal supplements?

A: While the official label focuses on interactions with prescription and specific OTC medicines, patients are generally advised to discuss all prescription, over-the-counter (OTC) medicines, vitamins, and herbal products they are using with their healthcare provider. This helps monitor for any potential interactions.

Q: Does Quinofree interact with alcohol?

A: Official regulatory documents typically do not list a direct chemical interaction between Ofloxacin and alcohol. Consultation with a healthcare provider about alcohol consumption is suggested, as excessive alcohol intake is generally understood to potentially affect the body's immune response while fighting an infection.

Q: Is Quinofree used for respiratory infections?

A: Yes, Quinofree is officially indicated for the treatment of certain respiratory tract infections, such as community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis, provided the infection is caused by a susceptible type of bacteria.

Q: Do I need a follow-up appointment after taking Quinofree?

A: Regulatory guidelines suggest that if an infection is not improved after one week of treatment, or if certain ear infections persist after the full course, further medical evaluation is recommended. The need for a routine follow-up is based on the specific condition being treated, which a healthcare provider can assess.

Q: How long until the side effects of Quinofree usually go away?

A: The timeline for common side effects is not specifically defined in regulatory documents. However, it is noted that some serious adverse reactions, such as tendon problems or nerve damage (peripheral neuropathy), may be delayed in onset, appearing even months after stopping the drug, and could potentially be long-lasting.

Q: Is Quinofree effective against MRSA?

A: Quinofree (Ofloxacin) is indicated for skin infections caused by methicillin-susceptible Staphylococcus aureus (MSSA). Its effectiveness for treating infections specifically caused by Methicillin-Resistant S. aureus (MRSA) is not listed in the standard regulatory indications.

Q: Does my diet need to change while I'm on Quinofree?

A: The drug can be taken with or without food as it does not significantly impact overall absorption. The primary concern is that it is necessary to separate administration by at least two hours from products or supplements containing multivalent cations like calcium, iron, or zinc, as these can interfere with the drug's absorption.

Q: Do I need to avoid sun exposure while on Quinofree?

A: Official safety information indicates that Quinofree can cause increased sensitivity to sunlight (photosensitivity). The official label suggests minimizing exposure to direct sunlight. Using protective measures, such as clothing and broad-spectrum sunscreen, may help reduce the risk of a severe sunburn reaction.

Q: How does Quinofree's mechanism of action compare to penicillin?

A: Quinofree works by targeting specific enzymes within the bacterial cell, DNA gyrase and Topoisomerase IV, which stops the bacteria from copying its genetic material. Penicillin, in contrast, belongs to a different class that generally works by disrupting the bacteria's cell wall formation. Both mechanisms are designed to kill the bacterial cells.

Q: Is there a generic version of Quinofree available?

A: Yes, the active ingredient in Quinofree is Ofloxacin, which is widely available as a generic drug. Generic Ofloxacin is approved by regulatory bodies in various forms, including tablets and topical solutions, as being therapeutically equivalent to the brand name product.

Q: Why is Quinofree considered a broad-spectrum medicine?

A: Quinofree is classified as a broad-spectrum antimicrobial because it has official approval for use against a wide range of different types of susceptible bacteria. This includes both Gram-negative and Gram-positive microorganisms, making it effective for various infections.

How should Quinofree be stored and disposed of?

Quinofree should be stored in its original, tightly closed container at room temperature, generally between 68 F to 77 F (20 C to 25 C), unless otherwise specified on the packaging. Protect the medication from excessive heat, moisture, and direct light, and do not freeze it. Always keep this medication, and all others, out of the reach of children and pets to prevent accidental ingestion.

Regarding disposal, it is essential to discard any expired or unused Quinofree safely. The preferred method for disposal is utilizing a local drug take-back program or event, such as those sponsored by the DEA, or using a drug mail-back envelope. If take-back options are unavailable, the medicine should not be flushed down the toilet (unless it is on the FDA's specific flush list) or thrown directly into the trash. Instead, mix the medication (without crushing tablets) with an undesirable substance like cat litter or used coffee grounds, place the mixture in a sealed bag or container, and then dispose of it in household trash. Scratch out all personal information on the prescription label before discarding the empty container.

Quinofree